Client News

Formycon reports key operational achievements in the first half of 2026 and significantly improves financial results year-on-year

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod

InflaRx to Report Second Quarter 2026 Results on August 6, 2026

Promatix Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Advance First-in-Class EGFR × EphA2 Cis-Bispecific ADC

NVision Advances Its Quantum Platform With Expansion Into South Korea

Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments

Novogenia AG Invests in State-of-the-Art Healthcare and Manufacturing Technologies at Its New Hallwang Headquarters

Darwin AG becomes Novogenia AG, strengthening its international position

Formycon AG and OneSource Specialty Pharma announce strategic Manufacturing Partnership for Biosimilars